[Home ] [Archive]    
:: Home :: About Journal :: Registration :: Article Submission :: Contact us :: Site Map ::
:: Volume 9, Issue 4 (December 2017 2017) ::
IJBC 2017, 9(4): 108-111 Back to browse issues page
The Comparison of Efficacy of Original Brand Deferoxamine with Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients with Thalassemia Major
Peyman Eshghi * , Ali Amin Asnafi , Ahmadreza Shamshiri , Samin Alavi , Mohammad Molavi , Ahmad Tamaddoni , Bijan Keikhaie , Majid Naderi , Hamid Hoorfar , Shahla Ansari , Azita Azarkeivan , Majid Arasteh , Zahra Kourorian
Abstract:   (744 Views)
Background: Deferoxamine mesylate is still the conventional and well-known iron chelator for patients with thalassemia major. However, due to some marketing issues the well-known original brand, Desferal®, produced by Novartis Pharmaceuticals Company is not as available as before. The generic brands of Deferoxamine have been introduced in many parts of the world including Iran; however, they are not well accepted by the physicians and patients yet. This triple-blind randomized controlled trial was designed to compare the efficacy and safety of a new Iranian generic and the original brand product of Deferoxamine mesylate in Iranian patients. 
Methods: The present Randomized triple-blind controlled trial research was carried on  in nine centers throughout Iran. They were randomly divided into two similar groups and a Cross-over study was designed. 24-hour urine was collected after subcutaneous infusion of either drugs and urinary iron excretion was measured via atomic absorption spectrophotometer device. Acute adverse events during and after drug infusion were recorded. Mack Nara test and p-pair test were applied to compare two cross over interventions. 
Results: 154 patients from 9 centers were enrolled in this study. There were 95 women and 59 men aged 6-34 years (mean age of 21.1years). Mean urinary iron concentration for Desferal (intervention A) vs. Desfonak (intervention B) groups was 22.5±22.6 vs. 21.5±16.9 mg/m2 , respectively. Mean urinary iron excretion/Kg body weight for Desferal (intervention A) vs. Desfonak (intervention B) groups was 0.48±0.48 vs. 0.47±0.40 mg/m2, respectively. 
Conclusion: According to the results of this study, there was similarity between efficacy and safety of the original and generic brands of deferoxamine (desferal vs. desfonac).
Keywords: Thalassemia major, Iron chelation, Urinary iron excretion, Atomic absorption spectrophotometry Deferoxamine mesylate
Full-Text [PDF 897 kb]   (410 Downloads)    
: Research | Subject: Pediatric Hematology & Oncology
Received: 2018/02/28 | Accepted: 2018/02/28 | Published: 2018/02/28
Add your comments about this article
Your username or Email:

CAPTCHA code


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Eshghi P, Amin Asnafi A, Shamshiri A, Alavi S, Molavi M, Tamaddoni A, et al . The Comparison of Efficacy of Original Brand Deferoxamine with Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients with Thalassemia Major. IJBC. 2017; 9 (4) :108-111
URL: http://ijbc.ir/article-1-790-en.html


Volume 9, Issue 4 (December 2017 2017) Back to browse issues page
مجله ی خون و سرطان ایران Iranian Journal of Blood and Cancer
Persian site map - English site map - Created in 0.05 seconds with 31 queries by YEKTAWEB 3796